Annexon, Inc.
General ticker "ANNX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $722.3M (TTM average)
Annexon, Inc. follows the US Stock Market performance with the rate: 45.1%.
Estimated limits based on current volatility of 3.4%: low 4.89$, high 5.24$
Factors to consider:
- Earnings expected soon, date: 2026-08-13 bmo
- Total employees count: 96 (-4.0%) as of 2025
- Top business risk factors: Limited operating history, No approved products, Clinical trial failure, Regulatory and compliance, Market competition
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.20$, 8.13$]
- 2026-12-31 to 2027-12-31 estimated range: [2.58$, 6.69$]
Financial Metrics affecting the ANNX estimates:
- Positive: with PPE of -3.7 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -23.59 <= 0.30
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 24.06 > -0.65
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Industry operating income (median)
Short-term ANNX quotes
Long-term ANNX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $143.72MM | $154.07MM | $216.41MM |
| Operating Income | $-143.72MM | $-154.07MM | $-216.41MM |
| Non-Operating Income | $9.49MM | $15.87MM | $9.72MM |
| R&D Expense | $113.76MM | $119.45MM | $184.70MM |
| Income(Loss) | $-134.24MM | $-138.20MM | $-206.69MM |
| Net Income(Loss)* | $-134.24MM | $-138.20MM | $-206.69MM |
| Stockholders Equity | $250.56MM | $293.11MM | $211.65MM |
| Assets | $297.67MM | $350.07MM | $277.57MM |
| Operating Cash Flow | $-121.14MM | $-118.01MM | $-186.36MM |
| Capital expenditure | $0.19MM | $0.01MM | $0.14MM |
| Investing Cash Flow | $70.70MM | $-218.80MM | $190.05MM |
| Financing Cash Flow | $135.52MM | $161.21MM | $108.86MM |
| Earnings Per Share** | $-1.77 | $-1.01 | $-1.33 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.